These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21937680)

  • 1. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.
    Sitohy B; Nagy JA; Jaminet SC; Dvorak HF
    Cancer Res; 2011 Nov; 71(22):7021-8. PubMed ID: 21937680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.
    Nagy JA; Dvorak HF
    Clin Exp Metastasis; 2012 Oct; 29(7):657-62. PubMed ID: 22692562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
    Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
    Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.
    Dvorak HF
    Cancer J; 2015; 21(4):237-43. PubMed ID: 26222073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
    Sitohy B; Nagy JA; Dvorak HF
    Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Permeability properties of tumor surrogate blood vessels induced by VEGF-A.
    Nagy JA; Feng D; Vasile E; Wong WH; Shih SC; Dvorak AM; Dvorak HF
    Lab Invest; 2006 Aug; 86(8):767-80. PubMed ID: 16732297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.
    Saaristo A; Veikkola T; Enholm B; Hytönen M; Arola J; Pajusola K; Turunen P; Jeltsch M; Karkkainen MJ; Kerjaschki D; Bueler H; Ylä-Herttuala S; Alitalo K
    FASEB J; 2002 Jul; 16(9):1041-9. PubMed ID: 12087065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay.
    Nagy JA; Shih SC; Wong WH; Dvorak AM; Dvorak HF
    Methods Enzymol; 2008; 444():43-64. PubMed ID: 19007660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of the tumor vasculature.
    Nagy JA; Chang SH; Shih SC; Dvorak AM; Dvorak HF
    Semin Thromb Hemost; 2010 Apr; 36(3):321-31. PubMed ID: 20490982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
    Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
    Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.
    Awazu Y; Mizutani A; Nagase Y; Tsuchiya S; Nakamura K; Kakoi Y; Kitahara O; Takeuchi T; Yamasaki S; Miyamoto N; Iwata H; Miki H; Imamura S; Hori A
    Cancer Sci; 2013 Apr; 104(4):486-94. PubMed ID: 23305239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery.
    Sundberg C; Nagy JA; Brown LF; Feng D; Eckelhoefer IA; Manseau EJ; Dvorak AM; Dvorak HF
    Am J Pathol; 2001 Mar; 158(3):1145-60. PubMed ID: 11238063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors.
    Lassoued W; Murphy D; Tsai J; Oueslati R; Thurston G; Lee WM
    Cancer Biol Ther; 2010 Dec; 10(12):1326-33. PubMed ID: 21079419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A.
    Kadambi A; Mouta Carreira C; Yun CO; Padera TP; Dolmans DE; Carmeliet P; Fukumura D; Jain RK
    Cancer Res; 2001 Mar; 61(6):2404-8. PubMed ID: 11289105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.